RBC Capital Sticks to Its Buy Rating for Corbus Pharmaceuticals (CRBP)
In a report released on February 11, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research ...
RBC Capital Sticks to Its Buy Rating for Pegasystems (PEGA)
RBC Capital analyst Rishi Jaluria maintained a Buy rating on Pegasystems (PEGA – Research Report) yesterday and set a price target of $115.00.
RBC Capital lifts Q2 Holdings stock target to $108
RBC Capital Markets adjusted its price target for Q2 Holdings stock, raising it to $108 from the previous $105, while maintaining a Sector Perform rating. The increase follows Q2 Holdings' report of ...
Aardvark Therapeutics, Inc.: Aardvark Therapeutics Announces Pricing of Initial Public Offering
Aardvark Therapeutics, Inc. ("Aardvark") (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Aardvark Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate ...
FLOWERS FOODS, INC. PRICES $500 MILLION OF 5.750% SENIOR NOTES DUE 2035 AND $300 MILLION OF 6.200% SENIOR NOTES DUE 2055
Flowers Foods, Inc. (NYSE: FLO) (the "Company" or "Flowers Foods") today announced the pricing of the public offering of (i) $500 million aggregate principal amount of 5.750% Senior Notes due 2035 ...
RBC Capital maintains Outperform on Palo Alto Networks stock, $225 target
RBC Capital Markets reaffirmed their positive stance on Palo Alto Networks (NASDAQ:PANW), maintaining an Outperform rating and a $225.00 price target for the cybersecurity company's shares. The stock, ...